These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 15086478)

  • 1. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplantation in patients with Fabry disease.
    Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
    Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
    Furujo M; Kubo T; Kobayashi M; Ohashi T
    Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
    Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
    J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
    Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
    Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.